



Multimeric Biotherapeutics, Inc.
("MultimericBio")
"Unlocking the potential of the TNF SuperFamily Ligands"

Multimeric Biotherapeutics, Inc. receives QTDP stimulus grant to develop new vaccines

November 15, 2010, La Jolla, CA – Multimeric Biotherapeutics, Inc. ("MultimericBio") announced the receipt of a grant for \$80,770 from the Federal Government's Qualifying Therapeutic Discovery Project (QTDP) Program. The grant is directed towards supporting Multimeric Biotherapeutics' previously funded NIH grant supporting the developing a novel nicotine vaccine, aimed at helping smokers quit cigarettes.

"These funds will prove particularly useful to us as we continue to advance our novel vaccines towards the clinic," said Richard S. Kornbluth, M.D., Ph.D., President and Chief Scientific Officer at Multimeric Biotherapeutics.

Cigarette smoking is the leading preventable cause of death in the U.S. and accounts for about 1 of every 5 deaths (438,000 people) each year. Vaccines against nicotine are designed to generate antibodies that sequester inhaled nicotine in the blood, thereby preventing it from crossing into the brain and re-enforcing the nicotine habit. When combined with an abstinence program and counseling, a nicotine vaccine is anticipated to help smokers eliminate cigarettes from their lives.

If the early testing is successful, the company hopes to engage a Pharma partner to bring its new nicotine vaccine to patients. Two other companies developing nicotine vaccines have each found a major Pharma partner and entered into deals potentially worth \$500 million in each case. Consequently, the development of an effective nicotine vaccine would add significant value for MultimericBio's investors.

About the QTDP program

The QTDP's grants are provided under the new section 48D of the Internal Revenue Code (IRC), enacted as part of the Patient Protection and Affordable Care Act of 2010. The \$1.0 billion in funding and credits allocated to the federal QTDP Program are being distributed to U.S. companies with fewer than 250 employees whose research shows the greatest potential to result in new therapies that address areas of unmet medical need, those that could prevent, detect or treat chronic or acute diseases and conditions, and those that could significantly advance the goal of curing cancer within 30 years. Awards also took into consideration research that demonstrates the greatest potential to create and sustain high-quality, high-paying U.S. jobs and to advance U.S. competitiveness in life, biological and medical sciences, along with research that promises to reduce the long-term growth of health care costs in the U.S.

About Multimeric Biotherapeutics, Inc.

Multimeric Biotherapeutics, Inc. is a privately held, early-stage biotech company focused on applying CD40L and other TNF SuperFamily ligands for the prevention and treatment of disease. Its core, patented technology is being used to create next-generation vaccines and tumor immunotherapies. MultimericBio has offices in La Jolla, CA, and laboratories in Carlsbad, CA, both in the San Diego area. More information is available at www.multimericbio.com . Contact us at info@multimericbio.com